Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq Stockholm
20:00:00 17/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.12 SEK | 0.00% |
|
+0.18% | +108.24% |
| 11-12 | Lannebo Health and New Technology rose 7.2 percent in October - Bonesupport and Cellavision among the winners | FW |
| 11-11 | Sand Grove Capital increases stake in Egetis Therapeutics | FW |
| Market Cap | 5.17B 512M 465M 429M 387M 731M 47.81B 759M 2.05B 25.8B 1.92B 1.88B 81.51B | P/E 2026 * |
131x | P/E 2027 * | -43x |
|---|---|---|---|---|---|
| Enterprise Value | 4.24B 419M 381M 352M 317M 599M 39.19B 622M 1.68B 21.15B 1.57B 1.54B 66.81B | EV / Sales 2026 * |
37.5x | EV / Sales 2027 * | 8.69x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
| 0ABW | Delayed | ||
| PDPHF | Delayed | ||
| Real-time | |||
| P0F | Delayed | ||
| P0F | Real-time | ||
| P0F | Delayed | ||
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 week | +0.18% | ||
| Current month | +10.54% | ||
| 1 month | +20.35% | ||
| 3 months | +56.84% | ||
| 6 months | +64.25% | ||
| Current year | +108.24% |
| 1 week | 11.1 | 11.2 | |
| 1 month | 8.96 | 11.2 | |
| Current year | 4.23 | 11.2 | |
| 1 year | 3.62 | 11.2 | |
| 3 years | 3.02 | 11.2 | |
| 5 years | 3 | 11.2 | |
| 10 years | 3 | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 A | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 8/31/26 A | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 8/31/26 A | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | +0.18% | +89.44% | +126.94% | 512M | ||
| +1.15% | -2.81% | +55.79% | +71.12% | 65.56B | ||
| -2.64% | -1.13% | +7.82% | +88.90% | 60.41B | ||
| -1.07% | +0.30% | +22.91% | +86.76% | 55.76B | ||
| +0.48% | -2.53% | +9.73% | +121.14% | 46.98B | ||
| -2.69% | -6.38% | +19.19% | +25.79% | 43.63B | ||
| -0.70% | +4.93% | +17.77% | +45.03% | 36.7B | ||
| -2.50% | -15.73% | +135.31% | +662.73% | 36.09B | ||
| -0.77% | -4.34% | +79.27% | +59.47% | 32.9B | ||
| -0.83% | +1.98% | -38.27% | +390.98% | 26.96B | ||
| Average | -0.96% | -2.06% | +39.90% | +167.88% | 41B | |
| Weighted average by Cap. | -0.99% | -2.21% | +34.18% | +147.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 11.18M 10.15M 9.37M 8.46M 15.96M 1.04B 16.58M 44.67M 564M 41.94M 41.06M 1.78B | 512M 50.67M 45.99M 42.49M 38.33M 72.36M 4.73B 75.13M 202M 2.55B 190M 186M 8.07B |
| Net income | 414M 40.97M 37.19M 34.36M 31M 58.51M 3.83B 60.76M 164M 2.07B 154M 150M 6.53B | -120M -11.87M -10.77M -9.95M -8.98M -16.95M -1.11B -17.59M -47.42M -598M -44.52M -43.58M -1.89B |
| Net Debt | -932M -92.23M -83.73M -77.35M -69.78M -132M -8.62B -137M -369M -4.65B -346M -339M -14.69B | -720M -71.26M -64.69M -59.76M -53.91M -102M -6.66B -106M -285M -3.59B -267M -262M -11.35B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/11/26 | SEK 11.12 | 0.00% | 2,094,870 |
| 16/11/26 | SEK 11.12 | -0.71% | 1,703,374 |
| 13/11/26 | SEK 11.20 | +0.72% | 2,237,972 |
| 12/11/26 | SEK 11.12 | 0.00% | 2,578,051 |
| 11/11/26 | SEK 11.12 | +0.18% | 5,182,684 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
















